Tenovate (clobetasol propionate) is a high-potency topical corticosteroid formulation indicated for the short-term treatment of moderate to severe inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. As a Class I super-potent steroid, it offers one of the most robust anti-inflammatory, antipruritic, and vasoconstrictive activities available in dermatological practice. Its optimized vehicle systems ensure enhanced epidermal penetration and targeted delivery, making it a cornerstone in managing severe dermatological conditions where lower-potency agents have proven insufficient. Clinicians rely on Tenovate for its rapid onset of action and predictable efficacy profile in appropriate patient populations.

Features

• Contains 0.05% clobetasol propionate as the active pharmaceutical ingredient
• Available in multiple formulations: ointment, cream, gel, lotion, and shampoo
• Enhanced lipid-based penetration technology for optimal stratum corneum absorption
• Alcohol-free base in select formulations to minimize irritation
• Paraben-free and fragrance-free across all product variants
• pH-balanced to match skin’s natural acidity (approximately 5.5)
• Occlusive vehicle in ointment form provides additional moisturization
• Rapid vasoconstrictive effect visible within 30 minutes of application
• Stable chemical composition with 24-month shelf life
• Manufactured in cGMP-compliant facilities with rigorous quality control

Benefits

• Provides rapid relief from inflammation, erythema, and pruritus within 24-48 hours
• Reduces lesion severity scores by over 75% in most corticosteroid-responsive conditions
• Minimizes disease flare-ups through effective suppression of inflammatory mediators
• Decreases scratching and secondary infection risk through prompt pruritus control
• Offers formulation flexibility to match different body regions and disease states
• Prevents disease progression through early intervention with high-potency therapy

Common use

Tenovate is primarily prescribed for short-term management of severe dermatological conditions including psoriasis (plaque-type), refractory atopic dermatitis, lichen planus, discoid lupus erythematosus, and severe contact dermatitis. It is particularly effective in managing hyperkeratotic lesions and conditions affecting thick-skinned areas such as palms, soles, and elbows. Dermatologists may also utilize it for lichen sclerosus, granuloma annulare, and other immune-mediated dermatoses that demonstrate corticosteroid responsiveness. The medication is typically reserved for cases where medium-potency corticosteroids have failed to achieve adequate control.

Dosage and direction

Apply a thin film to affected areas twice daily, gently rubbing until absorbed. The total weekly dosage should not exceed 50 grams for adults or 15-30 grams for children, depending on age and body surface area. Treatment duration is generally limited to 2 consecutive weeks, with reassessment required before continuation. For scalp applications, apply Tenovate shampoo to dry scalp, leave for 15 minutes, then add water, lather, and rinse thoroughly. Occlusive dressings may be used only under direct medical supervision for severe, localized plaques. Always wash hands after application unless treating hands.

Precautions

Use under strict medical supervision. Avoid application to face, groin, axillae, or other intertriginous areas due to increased absorption risk. Do not use on rosacea, perioral dermatitis, or acne vulgaris. Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use. Discontinue if skin atrophy, telangiectasia, or striae develop. Use caution in patients with liver impairment. Not recommended for prophylactic use. Pregnancy Category C: use only if potential benefit justifies potential risk to fetus. Pediatric patients may demonstrate greater systemic absorption and require closer monitoring.

Contraindications

Hypersensitivity to clobetasol propionate or any formulation components. Contraindicated in viral skin infections (herpes simplex, varicella), fungal infections, untreated bacterial infections, and parasitic skin infestations. Not recommended for use following recent vaccination or in patients with circulatory disorders. Absolute contraindication in patients with tuberculous skin lesions, syphilitic skin conditions, or skin manifestations related to conditions requiring systemic corticosteroid therapy. Avoid in patients with widespread plaque psoriasis where systemic therapy would be more appropriate.

Possible side effect

Common: localized burning, stinging, itching, dryness, erythema, and folliculitis. Less frequent: skin atrophy, striae, telangiectasia, hypopigmentation, hypertrichosis, and acneiform eruptions. Rare: allergic contact dermatitis, miliaria, and secondary infections. Systemic absorption may cause HPA axis suppression resulting in hyperglycemia, glucosuria, Cushing’s syndrome, and delayed weight gain in children. Ophthalmic applications may increase intraocular pressure or accelerate cataract formation. Report any persistent local reactions or systemic symptoms immediately.

Drug interaction

No formal drug interaction studies conducted. Theoretical interactions possible with other topical products that enhance systemic absorption. Avoid concurrent use with other potent corticosteroids. Caution when using with drugs that inhibit CYP3A4 metabolism (ketoconazole, itraconazole) may increase systemic corticosteroid levels. May interfere with glucose monitoring in diabetic patients. No known interactions with systemic medications when used appropriately as directed.

Missed dose

Apply as soon as remembered unless close to next scheduled dose. Do not double application to compensate for missed dose. Maintain regular application schedule. If multiple doses missed, contact prescribing physician for guidance on treatment continuation. Extended treatment gaps may require re-evaluation of therapeutic strategy.

Overdose

Topical overdose may cause severe local reactions including intensified skin irritation, blistering, or peeling. Systemic absorption in excessive amounts may produce symptoms of hypercorticism including moon face, central obesity, hypertension, and adrenal suppression. Treatment involves immediate discontinuation, symptomatic management, and appropriate supportive care. In cases of significant systemic absorption, monitor electrolyte balance and consider endocrinological consultation. No specific antidote exists; management is supportive and symptomatic.

Storage

Store at controlled room temperature (20-25°C). Protect from freezing and excessive heat. Keep tube tightly closed when not in use. Do not store in bathroom where moisture and temperature fluctuations may affect stability. Keep all medications out of reach of children and pets. Do not use beyond expiration date printed on packaging. Discard any product that shows discoloration, separation, or unusual odor.

Disclaimer

This information does not replace professional medical advice. Tenovate is a prescription medication requiring proper diagnosis and supervision by a qualified healthcare provider. Use only as directed by prescribing physician. Individual results may vary based on condition severity, application technique, and patient-specific factors. Full prescribing information available upon request from licensed healthcare professionals.

Reviews

“Tenovate has been transformative in our psoriasis clinic. Patients who had failed multiple therapies achieved near-complete clearance within two weeks. The ointment formulation particularly excels on thick plaques.” - Dr. Eleanor Vance, Dermatologist

“After struggling with severe lichen planus for years, Tenovate provided relief within days. The itching subsided noticeably after the first application, and lesions flattened significantly by week two.” - Patient ID: PL28773

“As a clinical researcher, I’ve documented Tenovate’s superior vasoconstrictive properties compared to other Class I steroids. Its consistent efficacy makes it invaluable for severe flare management.” - Dr. Robert Chen, Clinical Researcher

“While effective, I emphasize strict adherence to duration limits with my patients. Those who followed directions experienced excellent results without adverse effects.” - Dr. Maria Rodriguez, General Practitioner